New drug trial aims to strengthen fragile bones in children
NCT ID NCT06636071
Summary
This study is testing whether a drug called setrusumab can help reduce the number of broken bones in Japanese children with osteogenesis imperfecta (OI), also known as brittle bone disease. Six children with specific types of OI will receive the drug for at least two years. The main goal is to see if the treatment lowers the yearly rate of fractures, including spine fractures.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Keio University Hospital
Tokyo, Japan
-
Osaka Metropolitan University Hospital
Osaka, Japan
-
Osaka University Hospital
Osaka, Japan
Conditions
Explore the condition pages connected to this study.